Nivolumab Tested Against Placebo in Relapsed Mesothelioma in a 332-Patient Phase 3 Trial
A completed phase 3 trial tested the PD-1 inhibitor nivolumab against placebo in relapsed mesothelioma. The registry entry lists no results.
Summary
Mesothelioma, a cancer linked to asbestos, has no standard treatment once it returns after pemetrexed and cisplatin chemotherapy. This UK trial, called CONFIRM, tested nivolumab, an immunotherapy that blocks the PD-1 checkpoint on T-cells. PD-1 normally acts as a brake on these immune cells, and early research suggested mesothelioma depends on that brake. Blocking it could let the immune system attack the tumor. The trial was randomized, double blind and placebo controlled. It enrolled 332 patients whose disease had relapsed for the second or third time after platinum-based chemotherapy. It is listed as completed, with a start date of March 2017 and a completion date of February 2023, and was sponsored by the University of Southampton. The registry record we reviewed contains no outcome data, so we cannot say whether nivolumab extended survival or caused harm. Readers should treat this as a well-designed test of a plausible mechanism, not as evidence of benefit.
Detailed Summary
Mesothelioma is an aggressive cancer of the lining of the lungs and other organs, tied to asbestos exposure. The abstract notes that UK incidence has risen 497% since the late 1970s and that it is still increasing worldwide. For patients who relapse after pemetrexed and cisplatin there is no standard treatment, and recent trials have not found a therapy that improves overall survival.
This trial, CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM), tested nivolumab, an antibody against the PD-1 receptor on activated T-cells. PD-1 normally switches T-cells off. Blocking it is meant to keep them active against tumor cells. The abstract says early research found mesothelioma depends on this checkpoint, and that PD-1 inhibition has transformed melanoma treatment. The trial was designed after a national survey ranked immunotherapy a top research priority.
The design was a phase 3, randomized, double-blind, placebo-controlled trial. It enrolled 332 patients with mesothelioma in their second or third relapse after platinum-based chemotherapy. Patients received either nivolumab or placebo. The University of Southampton sponsored it. It began on March 28, 2017 and is listed as completed on February 7, 2023.
The record we reviewed reports no results. There is no survival figure, response rate or adverse event data, so we cannot say whether nivolumab helped, did nothing or caused harm. Any statement about efficacy would be speculation.
What the entry does show is a rigorous design aimed at a clear mechanism in a setting of urgent unmet need. A placebo control and double blinding in relapsed disease give the trial strong potential to answer the question reliably. Clinicians should look for the published primary results, particularly overall survival and toxicity, before changing practice.
Caveats: this summary rests on the registry abstract only. It does not describe endpoints, dosing, statistical plans or outcomes. A completed trial is not a positive trial.
Key Findings
- Phase 3, randomized, double-blind, placebo-controlled trial of nivolumab in relapsed mesothelioma.
- Enrolled 332 patients in second or third relapse after platinum-based chemotherapy.
- Mechanism tested: PD-1 blockade to release the T-cell brake, based on early evidence of mesothelioma dependence on PD-1.
- Registry record lists the trial as completed (February 2023) but reports no efficacy or safety results.
Methodology
Phase 3, randomized, double-blind, placebo-controlled trial run by the University of Southampton, with 332 participants. Patients had mesothelioma in second or third relapse after platinum-based chemotherapy. They received nivolumab or placebo. Endpoints are not stated in the abstract.
Study Limitations
This summary is based on the registry abstract only, which gives no results, endpoints, dosing or safety data. Efficacy and harms are unknown from this source. A completed status does not indicate a positive or negative outcome.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
